

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Duality Biotherapeutics, Inc.

映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock code: 9606)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026

References are made to the notice of annual general meeting (the “**Notice**”) and the circular (the “**Circular**”) of Duality Biotherapeutics, Inc. (the “**Company**”) both dated June 4, 2026. Unless otherwise indicated, capitalized terms used herein have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll at the AGM.

The poll results in respect of the resolutions proposed at the AGM were as follows.

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2025.	49,208,881 (99.991872%)	4,000 (0.008128%)
2.	(a) To re-elect the following retiring directors of the Company (the “ Director(s) ”):		
	(i) Dr. HUA Haiqing as an executive Director.	49,057,623 (99.684518%)	155,258 (0.315482%)
	(ii) Mr. CAI Zhiyang as a non-executive Director.	49,056,725 (99.682693%)	156,156 (0.317307%)
	(iii) Mr. XIE Dong as an independent non-executive Director.	46,660,512 (94.813616%)	2,552,369 (5.186384%)
	(iv) Ms. CHUAI Shuyin as an independent non-executive Director.	47,252,286 (96.016094%)	1,960,595 (3.983906%)
	(b) To authorise the board (the “ Board ”) of Directors to fix the remuneration of the Directors.	49,199,077 (99.971950%)	13,804 (0.028050%)

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
3.	To re-appoint PricewaterhouseCoopers as auditors of the Company and authorise the Board to fix their remuneration.	46,444,560 (94.374804%)	2,768,321 (5.625196%)
4.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution.	49,208,881 (99.991872%)	4,000 (0.008128%)
5.	To grant a general mandate to the Directors to allot, issue and deal with shares of the Company and/or to sell or transfer treasury shares of the Company involving a maximum of 20% of the total number of shares of the Company in issue (excluding treasury shares) as at the date of passing of this resolution.	45,951,636 (93.373188%)	3,261,245 (6.626812%)
6.	To extend the general mandate granted under resolution no. 5 by adding the shares of the Company repurchased pursuant to the general mandate granted by resolution no. 4.	45,997,532 (93.466448%)	3,215,349 (6.533552%)

As more than 50% of the votes held by Shareholders present at the AGM in person or by proxy were cast in favour of resolutions no. 1 to no. 6, such resolutions were duly passed as ordinary resolutions of the Company.

For details of the above resolutions, Shareholders may refer to the Notice and the Circular.

As at the date for determining the Shareholders' entitlement to attend and vote at the AGM, the Company had 90,906,514 issued Shares. The total number of Shares entitling the Shareholders to attend and vote on the resolutions proposed at the AGM was 90,580,214 Shares. The 326,300 Shares held by the Company as treasury shares did not carry voting rights at the AGM and were excluded from the total number of Shares entitling Shareholders to attend and vote at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the AGM. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Hong Kong share registrar of the Company, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

All Directors attended the AGM in person or by electronic means.

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Hong Kong, June 26, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.